Chandra Vargeese - 16 Feb 2023 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
Chief Technology Officer, Head of Platform Discovery Sciences
Signature
/s/ Chandra Vargeese
Issuer symbol
WVE
Transactions as of
16 Feb 2023
Net transactions value
-$41,303
Form type
4
Filing time
17 Feb 2023, 19:15:16 UTC
Previous filing
27 Jul 2022
Next filing
07 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Sale $41,303 -10,249 -8.8% $4.03 106,624 16 Feb 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WVE Share Option (right to buy) Award $0 +295,400 $0.000000 295,400 17 Feb 2023 Ordinary Shares 295,400 $4.75 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 16, 2023, the reporting person sold 10,249 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2023. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F2 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.03 to $4.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 Includes 1,500 ordinary shares acquired on July 14, 2022, and 4,278 ordinary shares acquired on January 14, 2023, under the issuer's 2019 Employee Share Purchase Plan.
F4 The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.

Remarks:

Chief Technology Officer, Head of Platform Discovery Sciences